Regeneron’s Libtayo/Fianlimab LAGs Bristol’s Opdualag On Timing, But May Win On Efficacy

Company Looks At Coformulation

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

The PD-1/LAG-3 combination showed a high response rate in a small number of melanoma patients with prior PD-1 exposure.

Regeneron at ASCO • Source: Alaric DeArment

While it is still early days and small patient numbers, Regeneron Pharmaceuticals, Inc.’s combination of its PD-1 inhibitor Libtayo (cemiplimab) and LAG-3 inhibitor fianlimab showed an overall response rate (ORR) and median progression-free survival (PFS) in patients with advanced melanoma that so far looks favorable compared with Bristol Myers Squibb Company’s approved PD-1/LAG-3 combination, Opdualag (nivolumab and relatlimab-rmbw), especially in patients with prior adjuvant PD-1 therapy.

The Tarrytown, NY-based company presented data from its Phase I study for the combination at the American Society of Clinical...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from ASCO

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up

 
• By Alaric DeArment

Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease

 
• By Alaric DeArment

The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

ASCO 2024 Wrap-Up Podcast

 
• By Alaric DeArment

Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.   

China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights

 
• By Brian Yang and Dexter Jie Yan

US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.

More from Conferences

ESMO 24: NIAGARA – Trial Design Question Hangs Over Imfinzi’s Bladder Cancer Return

 
• By Alexandra Shimmings

AstraZeneca’s NIAGARA trial of perioperative Imfinzi in bladder cancer was positively received at the ESMO meeting but its design did not distinguish the contributions of each treatment portion to the overall effect – something that the US FDA is likely to have a view on.    

ESMO 24: Incyte’s Zynyz Finally Mounts The POD1UM

 
• By Alexandra Shimmings

Persistence has paid off for Incyte’s Zynyz in anal cancer with a Phase III win that should make up for a previous disappointment at the FDA and give a boost to the firm’s pipeline prospects for a post-Jakafi era.    

Sutro Works Toward A Better Ovarian Cancer ADC

 
• By Mandy Jackson

Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.